2.14 USD
+0.04 (+1.9%)
Overall AMS gets a fundamental rating of 2 out of 10. We evaluated AMS against 102 industry peers in the Health Care Providers & Services industry. AMS has a bad profitability rating. Also its financial health evaluation is rather negative. AMS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year AMS has reported negative net income.
AMS had a positive operating cash flow in the past year.
Of the past 5 years AMS 4 years were profitable.
Each year in the past 5 years AMS had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of -3.84%, AMS is not doing good in the industry: 64.71% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -9.97%, AMS is in line with its industry, outperforming 43.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.84% | ||
| ROE | -9.97% | ||
| ROIC | N/A |
ROA(3y)2.64%
ROA(5y)-1.57%
ROE(3y)5.84%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of AMS has grown nicely.
AMS's Operating Margin has declined in the last couple of years.
AMS has a Gross Margin (24.43%) which is comparable to the rest of the industry.
AMS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for AMS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 24.43% |
OM growth 3Y-20.48%
OM growth 5Y-14.68%
PM growth 3Y92.72%
PM growth 5Y19.22%
GM growth 3Y-5.31%
GM growth 5Y-0.7%
2. Health
2.1 Basic Checks
AMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
AMS has more shares outstanding than it did 1 year ago.
AMS has more shares outstanding than it did 5 years ago.
AMS has a worse debt/assets ratio than last year.
2.2 Solvency
AMS has an Altman-Z score of 0.85. This is a bad value and indicates that AMS is not financially healthy and even has some risk of bankruptcy.
AMS has a Altman-Z score of 0.85. This is in the lower half of the industry: AMS underperforms 74.51% of its industry peers.
A Debt/Equity ratio of 0.58 indicates that AMS is somewhat dependend on debt financing.
AMS's Debt to Equity ratio of 0.58 is in line compared to the rest of the industry. AMS outperforms 57.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.85 |
ROIC/WACCN/A
WACC9.47%
2.3 Liquidity
AMS has a Current Ratio of 1.17. This is a normal value and indicates that AMS is financially healthy and should not expect problems in meeting its short term obligations.
AMS has a Current ratio (1.17) which is comparable to the rest of the industry.
A Quick Ratio of 1.17 indicates that AMS should not have too much problems paying its short term obligations.
AMS has a Quick ratio (1.17) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.17 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The earnings per share for AMS have decreased strongly by -950.00% in the last year.
Measured over the past years, AMS shows a very strong growth in Earnings Per Share. The EPS has been growing by 24.28% on average per year.
AMS shows a strong growth in Revenue. In the last year, the Revenue has grown by 32.90%.
Measured over the past years, AMS shows a small growth in Revenue. The Revenue has been growing by 6.58% on average per year.
EPS 1Y (TTM)-950%
EPS 3Y121.52%
EPS 5Y24.28%
EPS Q2Q%100%
Revenue 1Y (TTM)32.9%
Revenue growth 3Y17.14%
Revenue growth 5Y6.58%
Sales Q2Q%2.46%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y44.91%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.01%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AMS. In the last year negative earnings were reported.
Also next year AMS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMS indicates a rather cheap valuation: AMS is cheaper than 97.06% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 3.49 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for AMS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSEARCA:AMS (12/26/2025, 8:04:00 PM)
2.14
+0.04 (+1.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners12.71%
Inst Owner Change-2.58%
Ins Owners35.35%
Ins Owner Change4.52%
Market Cap14.00M
Revenue(TTM)28.34M
Net Income(TTM)-2.44M
Analysts80
Price Target4.59 (114.49%)
Short Float %0.19%
Short Ratio0.33
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.21%
Min EPS beat(2)0.99%
Max EPS beat(2)43.42%
EPS beat(4)2
Avg EPS beat(4)-543.23%
Min EPS beat(4)-2080.2%
Max EPS beat(4)43.42%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.46%
Min Revenue beat(2)-3.97%
Max Revenue beat(2)-0.96%
Revenue beat(4)1
Avg Revenue beat(4)0.93%
Min Revenue beat(4)-7.97%
Max Revenue beat(4)16.61%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-9.09%
EPS NY rev (3m)-9.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-1.19%
Revenue NY rev (3m)-1.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.48 | ||
| P/FCF | N/A | ||
| P/OCF | 4.86 | ||
| P/B | 0.57 | ||
| P/tB | 0.6 | ||
| EV/EBITDA | 3.49 |
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-1.31
FCFYN/A
OCF(TTM)0.44
OCFY20.56%
SpS4.47
BVpS3.74
TBVpS3.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.84% | ||
| ROE | -9.97% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 24.43% | ||
| FCFM | N/A |
ROA(3y)2.64%
ROA(5y)-1.57%
ROE(3y)5.84%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)6.05%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-20.48%
OM growth 5Y-14.68%
PM growth 3Y92.72%
PM growth 5Y19.22%
GM growth 3Y-5.31%
GM growth 5Y-0.7%
F-Score4
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.28 | ||
| Cap/Depr | 182.58% | ||
| Cap/Sales | 39.16% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 46.15% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.17 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 0.85 |
F-Score4
WACC9.47%
ROIC/WACCN/A
Cap/Depr(3y)86.06%
Cap/Depr(5y)59.68%
Cap/Sales(3y)19.8%
Cap/Sales(5y)14.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-950%
EPS 3Y121.52%
EPS 5Y24.28%
EPS Q2Q%100%
EPS Next Y44.91%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)32.9%
Revenue growth 3Y17.14%
Revenue growth 5Y6.58%
Sales Q2Q%2.46%
Revenue Next Year8.01%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-101.77%
EBIT growth 3Y-6.85%
EBIT growth 5Y-9.07%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-255.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.59%
OCF growth 3Y-70.14%
OCF growth 5Y-53.93%
AMERICAN SHARED HOSPITAL SER / AMS FAQ
What is the fundamental rating for AMS stock?
ChartMill assigns a fundamental rating of 2 / 10 to AMS.
Can you provide the valuation status for AMERICAN SHARED HOSPITAL SER?
ChartMill assigns a valuation rating of 1 / 10 to AMERICAN SHARED HOSPITAL SER (AMS). This can be considered as Overvalued.
How profitable is AMERICAN SHARED HOSPITAL SER (AMS) stock?
AMERICAN SHARED HOSPITAL SER (AMS) has a profitability rating of 3 / 10.
Can you provide the financial health for AMS stock?
The financial health rating of AMERICAN SHARED HOSPITAL SER (AMS) is 2 / 10.